MABVAX THERAPEUTICS (TELK)

2.75
0.25 8.33
OTC
Prev Close 3.00
Open 3.00
Day Low/High 2.75 / 3.00
52 Wk Low/High 1.01 / 16.48
Volume 2.62K
Exchange OTC
Shares Outstanding 1.83M
Market Cap 11.14M
Div & Yield N.A. (N.A)

5 Stocks Under $10 Set to Soar

These under-$10 stocks look ready to break out and trade higher from current levels.

3 Stocks Raising The Drugs Industry Higher

TheStreet highlights 3 stocks that pushed the Drugs industry

Why Telik (TELK) Stock Is Soaring Today

Telik (TELK) soared Tuesday after Monday's announcement that the oncology drug development company had entered into a definitive merger agreement with privately held MabVax Therapeutics.

Telik, Biotech Pariah, Finally Died

Telik never recovered from hiding the premature deaths of ovarian cancer patients treated with its experimental drug Telcyta in 2007

Icahn Should Hang It Up: Activist

Carl Icahn's days as an influential activist investor are over after his shameful performance on Yahoo!'s board.

Insider Sells $20.2 Million of National Semi

Jonathan Moreland, author of InsiderInsights, gives you the lowdown on top stock purchases and sales.

Feuerstein's Biotech-Stock Mailbag

A health stock rebound? Plus, my take on Onyx and M&A speculation fun.

Feuerstein's Biotech-Stock Mailbag

Pointing the finger at the FDA isn't a sound investment strategy.

Monday's Health Winners & Losers

Biogen Idec surges on buyout talk.

Feuerstein's Biotech-Stock Mailbag

This week, updates on Dendreon and Medarex.

Telik Fails Ethics Test

Management's behavior on its conference call shows the 80% decline was deserved.

These Homebuilder Stocks Could Soar

They're heavily shorted and could rise big on good news.

Wednesday's Health Winners & Losers

Oculus Innovative Sciences climbs on news of a drug licensing deal.

FDA Launches Inquiry Into Telik Trial

Regulators probe into why the company waited to report deaths in a cancer drug study.

Forget China, Bonds Spook Stocks

Rising Treasury yields prompt a setback amid more good economic news. Cody Willard wonders if this is 'as good as it gets.'

Tuesday's Health Winners & Losers

Telik tumbles on startling results for its experimental cancer treatment Telcyta.

FDA Halts Telik's Telcyta

Alarming results presented at ASCO spur the FDA to act on this Carl Icahn holding.

Monday's Health Winners & Losers

Cholestech and Digene soar on respective merger news.

Real Story: Echoes of '87

Woody Dorsey says the market is set up for another fateful fall.

Pushing the Upper Limits

Major averages approach records, but momentum is waning. Woody Dorsey says it looks like 1987 again.

Tuesday's Health Winners & Losers

Johnson & Johnson's rise on better-than-expected earnings boosted health care stocks.

Friday's Health Winners & Losers

Gene Logic is falling.

Stockpickr: How to Trade Like Carl Icahn

He recently added another cancer stock to his portfolio.

Stocks Find Post-Holiday Buyers

Microsoft and GM help lift the Dow.

Telik Plunges After Drug Disappoints

Telcyta fails to meet the preset goals of two separate late-stage clinical studies.

Icahn Likes H-P, Siebel, Rite Aid

He also reports bigger stakes in ImClone and Telik.

Telik Says Telcyta Data Positive

The company reports results of the treatment for advanced non-small cell lung cancer.

Investors Twice Shy on Cell Therapeutics

It's not surprising the stock is down since May, when the company dropped bullish hints about Xyotax.